Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans: A population-based study

Cancer

Volumn 118, Issue 22, 2012, Pages 5679-5687

  Reeve, Bryce B ^a   Stover, Angela M ^a   Jensen, Roxanne E ^b   Chen, Ronald C ^c   Taylor, Kathryn L ^b   Clauser, Steven B ^d   Collins, Sean P ^e   Potosky, Arnold L ^b  

^a IL   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

health related quality of life; older Americans; population based; prospective; prostate cancer

Indexed keywords

AGED; AGING; ANALYSIS OF COVARIANCE; BRACHYTHERAPY; CANCER REGISTRY; COHORT ANALYSIS; COMORBIDITY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; EDUCATION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MENTAL HEALTH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; SHORT FORM 36; SOCIAL STATUS; SURVEILLANCE,EPIDEMIOLOGY, AND END RESULTS REGISTRY; TUMOR CLASSIFICATION;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; DEPRESSIVE DISORDER, MAJOR; HEALTH STATUS; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SEER PROGRAM;

EID: 84868142581     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27578     Document Type: Review

References (54)

1. American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011.
2. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL,. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008; 148: 435-448.
3. Bacon CG, Giovannucci E, Testa M, Glass TA, Kawachi I,. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer. 2002; 94: 862-871.
4. Eton DT, Lepore SJ,. Prostate cancer and health-related quality of life: a review of the literature. Psychooncology. 2002; 11: 307-326.
5. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA. 2000; 283: 354-360.
6. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004; 96: 1358-1367.
7. Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007; 109: 2239-2247.
8. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358: 1250-1261.
9. Pardo Y, Guedea F, Aguilo F, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol. 2010; 28: 4687-4696.
10. Reeve BB, Potosky AL, Smith AW, et al. Impact of cancer on health-related quality of life of older Americans. J Natl Cancer Inst. 2009; 101: 860-868.
11. Hoffman RM, Gilliland FD, Penson DF, Stone SN, Hunt WC, Potosky AL,. Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer. 2004; 101: 2011-2019.
12. Ambs A, Warren JL, Bellizzi KM, Topor M, Haffer SC, Clauser SB,. Overview of the SEER-Medicare Health Outcomes Survey linked dataset. Health Care Financ Rev. 2008; 29: 5-21.
13. Jones N 3rd, Jones SL, Miller NA,. The Medicare Health Outcomes Survey program: overview, context, and near-term prospects [serial online]. Health Qual Life Outcomes. 2004; 2: 33.
14. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004 (based on the November 2006 SEER data submission). Bethesda, MD: National Cancer Institute; 2007. Available at: http://seer.cancer.gov/csr/1975- 2004/. Accessed October 13, 2011.
15. Rosenbaum PR, Rubin DB,. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983; 70: 41-55.
16. Rosenbaum PR, Rubin DB,. Constructing a control-group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985; 39: 33-38.
17. D'Agostino RB Jr,. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17: 2265-2281.
18. Reeve BB, Smith AW, Arora NK, Hays RD,. Reducing bias in cancer research: application of propensity score matching. Health Care Financ Rev. 2008; 29: 69-80.
19. Bergstralh E, Kosanke J,. GMATCH SAS Macro: computerized matching of cases to controls using the greedy matching algorithm with a fixed number of controls per case. Controls may be matched to cases using 1 or more factors (X's). Rochester, MN: Mayo Clinic; 2003. Available at: http://mayoresearch.mayo. edu/mayo/research/biostat/sasmacros.cfm. Accessed October 14, 2011.
20. Centers for Medicare and Medicaid Services. Medicare Health Outcomes Survey: report on the health status of managed care smokers and nonsmokers cohort III baseline and follow up. Final report prepared by Health Services Advisory Group [monograph online]. Available at: http://www.hosonline.org/ surveys/hos/download/HOS% 20Smoking%20Report%202005.pdf. Accessed October 14, 2011.
21. Ware JE Jr, Sherbourne CD,. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473-483.
22. Turner-Bowker DM, Bartley PJ, Ware JE Jr,. SF-36 Health Survey and "SF" Bibliography. 3rd ed. Lincoln, RI: QualityMetric Inc.; 2002.
23. Norman GR, Sloan JA, Wyrwich KW,. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003; 41: 582-592.
24. Robins LN, Helzer JE, Croughan J, Ratcliff KS,. National Institute of Mental Health Diagnostic Interview Schedule: its history, characteristics, and validity. Arch Gen Psychiatry. 1981; 38: 381-389.
25. Rost K, Burnam MA, Smith GR,. Development of screeners for depressive disorders and substance disorder history. Med Care. 1993; 31: 189-200.
26. Jagsi R, Abrahamse P, Hawley ST, Graff JJ, Hamilton AS, Katz SJ,. Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data. Cancer. 2012; 118: 333-341.
27. Virnig BA, Warren JL, Cooper GS, Klabunde CN, Schussler N, Freeman J,. Studying radiation therapy using SEER-Medicare-linked data. Med Care. 2002; 40: IV-49-IV-54.
28. Austin PC,. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008; 27: 2037-2049.
29. Ware JE, Kosinski M, Keller SK,. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institute; 1994.
30. Ware JE, Kosinski M,. SF-36 Physical and Mental Health Summary Scales: A Manual for Users of Version 1. 2nd ed. Lincoln, RI: QualityMetric Inc.; 2001.
31. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997; 337: 295-300.
32. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS,. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005; 103: 1615-1624.
33. Sadetsky N, Greene K, Cooperberg MR, Hubbard A, Carroll PR, Satariano W,. Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. Cancer. 2011; 117: 4406-4413.
34. Al-Mamgani A, van Putten WL, van der Wielen GJ, Levendag PC, Incrocci L,. Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial). Int J Radiat Oncol Biol Phys. 2011; 79: 1004-1012.
35. Little DJ, Kuban DA, Levy LB, Zagars GK, Pollack A,. Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study. Urology. 2003; 62: 707-713.
36. Lips I, Dehnad H, Kruger AB, et al. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys. 2007; 69: 656-661.
37. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011; 29: 1517-1524.
38. Mell LK, Mehrotra AK, Mundt AJ,. Intensity-modulated radiation therapy use in the US, 2004. Cancer. 2005; 104: 1296-1303.
39. Nelson CJ, Weinberger MI, Balk E, Holland J, Breitbart W, Roth AJ,. The chronology of distress, anxiety, and depression in older prostate cancer patients. Oncologist. 2009; 14: 891-899.
40. Burnet KL, Parker C, Dearnaley D, Brewin CR, Watson M,. Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int. 2007; 100: 540-543.
41. Diefenbach M, Mohamed NE, Horwitz E, Pollack A,. Longitudinal associations among quality of life and its predictors in patients treated for prostate cancer: the moderating role of age. Psychol Health Med. 2008; 13: 146-161.
42. Korfage IJ, Essink-Bot ML, Janssens AC, Schroder FH, de Koning HJ,. Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer. 2006; 94: 1093-1098.
43. Alibhai SM, Gogov S, Allibhai Z,. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol. 2006; 60: 201-215.
44. Morgan RO, Virnig BA, DeVito CA, Persily NA,. The Medicare-HMO revolving door-the healthy go in and the sick go out. N Engl J Med. 1997; 337: 169-175.
45. Pourat N, Kagawa-Singer M, Wallace SP,. Are managed care Medicare beneficiaries with chronic conditions satisfied with their care? J Aging Health. 2006; 18: 70-90.
46. Jensen GA, Morrisey MA,. Are healthier older adults choosing managed care? Gerontologist. 2004; 44: 85-94.
47. Donaldson GW, Moinpour CM,. Learning to live with missing quality-of-life data in advanced-stage disease trials. J Clin Oncol. 2005; 23: 7380-7384.
48. Addington-Hall J, Kalra L,. Who should measure quality of life? BMJ. 2001; 322: 1417-1420.
49. Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol. 2001; 19: 3750-3757.
50. Potosky AL, Reeve BB, Clegg LX, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst. 2002; 94: 430-437.
51. Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schroder FH,. Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. Prostate. 2001; 46: 87-97.
52. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002; 20: 557-566.
53. Korfage IJ, Essink-Bot ML, Borsboom GJ, et al. Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer. 2005; 116: 291-296.
54. Chen RC, Clark JA, Talcott JA,. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol. 2009; 27: 3916-3922.